# Multicenter Study of HGT-1110 Administered Intrathecally in Children With Metachromatic Leukodystrophy (MLD)

> **NCT01510028** · PHASE1,PHASE2 · COMPLETED · sponsor: **Shire** · enrollment: 24 (actual)

## Conditions studied

- Metachromatic Leukodystrophy (MLD)

## Interventions

- **BIOLOGICAL:** Recombinant human arylsulfatase A

## Key facts

- **NCT ID:** NCT01510028
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02-02
- **Primary completion:** 2017-01-20
- **Final completion:** 2017-01-20
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2021-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01510028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01510028, "Multicenter Study of HGT-1110 Administered Intrathecally in Children With Metachromatic Leukodystrophy (MLD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01510028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*